James R. Kasinger Crispr Therapeutics Ag (CRSP) insider trading activity

James R. Kasinger is General Counsel and Secretary of CRISPR Therapeutics AG. Currently has a direct ownership of 74,880 shares of CRSP, which is worth approximately $3.25 Million. The most recent transaction as insider was on Feb 19, 2025, when has been sold 1,947 shares (Common Shares) at a price of $52.8 per share, resulting in proceeds of $102,801. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 74.9K

19.62% 3M change

24.65% 12M change

Total Value Held $3.25 Million

JAMES R. KASINGER Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 19 2025	SELL Open market or private sale	$102,801 $52.8 p/Share	1,947 Reduced 2.53%	74,880 Common Shares
Feb 18 2025	SELL Open market or private sale	$516,690 $53.85 p/Share	9,595 Reduced 11.62%	73,002 Common Shares
Feb 18 2025	BUY Exercise of conversion of derivative security	-	3,825 Added 4.74%	76,827 Common Shares
Feb 16 2025	BUY Exercise of conversion of derivative security	-	20,000 Added 19.49%	82,597 Common Shares
Oct 14 2024	SELL Open market or private sale	$50,398 $46.28 p/Share	1,089 Reduced 1.71%	62,597 Common Shares
Oct 13 2024	BUY Exercise of conversion of derivative security	-	2,113 Added 3.21%	63,686 Common Shares
Mar 12 2024	SELL Open market or private sale	$85,308 $74.44 p/Share	1,146 Reduced 1.84%	61,174 Common Shares
Mar 11 2024	SELL Open market or private sale	$219,206 $78.26 p/Share	2,801 Reduced 4.46%	60,070 Common Shares
Mar 11 2024	BUY Exercise of conversion of derivative security	-	2,250 Added 3.48%	62,320 Common Shares
Mar 10 2024	BUY Exercise of conversion of derivative security	-	5,500 Added 8.04%	62,871 Common Shares
Feb 20 2024	SELL Open market or private sale	$152,408 $79.67 p/Share	1,913 Reduced 3.23%	57,371 Common Shares
Feb 18 2024	BUY Exercise of conversion of derivative security	-	3,825 Added 6.06%	59,284 Common Shares
Mar 13 2023	SELL Payment of exercise price or tax liability	$99,622 $43.22 p/Share	2,305 Reduced 4.03%	54,844 Common Shares
Mar 11 2023	BUY Exercise of conversion of derivative security	-	2,250 Added 3.87%	55,866 Common Shares
Mar 10 2023	BUY Exercise of conversion of derivative security	-	2,833 Added 4.91%	54,899 Common Shares
Feb 21 2023	SELL Payment of exercise price or tax liability	$94,107 $48.26 p/Share	1,950 Reduced 3.61%	52,066 Common Shares
Feb 18 2023	BUY Exercise of conversion of derivative security	-	3,825 Added 6.61%	54,016 Common Shares
Dec 05 2022	SELL Payment of exercise price or tax liability	$169,008 $52.26 p/Share	3,234 Reduced 6.05%	50,191 Common Shares
Dec 03 2022	BUY Exercise of conversion of derivative security	-	6,667 Added 11.09%	53,425 Common Shares
Mar 14 2022	SELL Payment of exercise price or tax liability	$63,462 $61.08 p/Share	1,039 Reduced 2.19%	46,429 Common Shares
Mar 11 2022	SELL Payment of exercise price or tax liability	$82,642 $62.56 p/Share	1,321 Reduced 2.84%	45,218 Common Shares
Mar 11 2022	BUY Exercise of conversion of derivative security	-	2,250 Added 4.53%	47,468 Common Shares
Mar 10 2022	BUY Exercise of conversion of derivative security	-	2,834 Added 5.74%	46,539 Common Shares
Dec 06 2021	SELL Payment of exercise price or tax liability	$435,978 $69.17 p/Share	6,303 Reduced 12.65%	43,542 Common Shares
Dec 03 2021	BUY Exercise of conversion of derivative security	-	13,333 Added 21.1%	49,845 Common Shares

JRK

James R. Kasinger

General Counsel and Secretary

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRSP shares.

Notify only if

Value

Insider Trading

Get notified when an Crispr Therapeutics Ag insider buys or sells CRSP shares.

Notify only if

Operation

Value

Type

News

Receive news related to CRISPR Therapeutics AG

Track Activities on CRSP

Account